Summit Therapeutics has entered into an exclusive license and commercialization agreement granting Eurofarma Laboratórios rights in Latin America to its precision antibiotic ridinilazole in development for the treatment of C. difficile (CDI). Summit retains rights in all other countries. Ridinilazole is a targeted antibiotic that has the potential as a frontline therapy to treat initial infection and preserve patients’ microbiomes to reduce the rate of recurrent CDI. In a Phase II trial in CD...